Efficacy of neoadjuvant endocrine therapy in patients with luminal HER2-negative breast cancer

Introduction. The biological heterogeneity of estrogen receptor-positive, HER2-negative breast cancer (ER+/HER2– BC) complicates the selection of optimal neoadjuvant therapy. Neoadjuvant endocrine therapy (NET) is a potential approach; however, its efficacy, particularly in premenopausal patients, remains insufficiently studied, and patient selection criteria require refinement. Objective. To evaluate the efficacy of NET in patients with ER+/HER2– BC based on pathological response, including the rates of pathological complete response (pCR), the composite endpoint RCB0+I (RCB, Residual Cancer Burden), and pathological complete response in the axillary lymph nodes (axillary pCR), and to identify clinicopathological factors associated with extensive residual cancer burden (RCB-III). Materials and methods. This single-center retrospective study included patients with stage I–III ER+/HER2– BC who received NET between 2019 and 2026. Pathological response was assessed using RCB. Factors associated with RCB-III were analyzed using Firth logistic regression. Results. A total of 263 patients were included: 59 (22.4%) were premenopausal and 204 (77.6%) were postmenopausal. The median age was 60 years, the median Ki-67 index was 25%, and the median progesterone receptor (PR) expression score was 7 on the Allred scale. Stage III disease was present in 88.6% of patients, and grade 2 tumors accounted for 93.2%. Disease worsening during NET was recorded in 56 (21.3%) patients: 30 (11.4%) were switched to neoadjuvant chemotherapy (NACT), and 26 (9.9%) underwent surgery. All 263 patients ultimately underwent surgery. Among the 233 patients who did not receive subsequent NACT, the rates of pCR, RCB0+I, and RCB-III were 0.9%, 4.3%, and 57.9%, respectively; among the 30 patients who received subsequent NACT, the corresponding rates were 13.3%, 16.7%, and 46.7%. Axillary pCR in patients with baseline cN+ disease was achieved in 9.6% (14/146) and 19.2% (5/26), respectively. In univariable analysis, baseline nodal involvement, higher estrogen receptor (ER) expression, and premenopausal status were associated with RCB-III; only the first two factors remained statistically significant after Holm correction. In multivariable analysis, all three factors were statistically significant. Conclusions. These findings support the potential use of NET as the sole preoperative systemic therapy in selected patients: 88.6% underwent surgery without NACT. Individualized treatment selection and regular response assessment are essential. The identified factors may help refine patient selection criteria. The prognostic significance of residual cancer burden requires further investigation incorporating long-term outcomes and accounting for adjuvant therapy.

Authors

Institutions

Publication Details

Journal
Medical alphabet
Published
2026-11-17
DOI
https://doi.org/10.33667/2078-5631-2026-27-74-82
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of neoadjuvant endocrine therapy in patients with luminal HER2-negative breast cancer

Елена Владимировна Артамонова, Мона Александровна Фролова, V. A. Fedko, Elena Igorevna Kovalenko et al.
Medical alphabet
Breast Cancer Treatment Studies
article

Efficacy of neoadjuvant endocrine therapy in patients with luminal HER2-negative breast cancer

Елена Владимировна Артамонова, Мона Александровна Фролова, V. A. Fedko, Elena Igorevna Kovalenko, Татьяна Александровна Титова, Ганьшина Инна Петровна, Элина Венеровна Янгирова
article en

Abstract

Introduction. The biological heterogeneity of estrogen receptor-positive, HER2-negative breast cancer (ER+/HER2– BC) complicates the selection of optimal neoadjuvant therapy. Neoadjuvant endocrine therapy (NET) is a potential approach; however, its efficacy, particularly in premenopausal patients, remains insufficiently studied, and patient selection criteria require refinement. Objective. To evaluate the efficacy of NET in patients with ER+/HER2– BC based on pathological response, including the rates of pathological complete response (pCR), the composite endpoint RCB0+I (RCB, Residual Cancer Burden), and pathological complete response in the axillary lymph nodes (axillary pCR), and to identify clinicopathological factors associated with extensive residual cancer burden (RCB-III). Materials and methods. This single-center retrospective study included patients with stage I–III ER+/HER2– BC who received NET between 2019 and 2026. Pathological response was assessed using RCB. Factors associated with RCB-III were analyzed using Firth logistic regression. Results. A total of 263 patients were included: 59 (22.4%) were premenopausal and 204 (77.6%) were postmenopausal. The median age was 60 years, the median Ki-67 index was 25%, and the median progesterone receptor (PR) expression score was 7 on the Allred scale. Stage III disease was present in 88.6% of patients, and grade 2 tumors accounted for 93.2%. Disease worsening during NET was recorded in 56 (21.3%) patients: 30 (11.4%) were switched to neoadjuvant chemotherapy (NACT), and 26 (9.9%) underwent surgery. All 263 patients ultimately underwent surgery. Among the 233 patients who did not receive subsequent NACT, the rates of pCR, RCB0+I, and RCB-III were 0.9%, 4.3%, and 57.9%, respectively; among the 30 patients who received subsequent NACT, the corresponding rates were 13.3%, 16.7%, and 46.7%. Axillary pCR in patients with baseline cN+ disease was achieved in 9.6% (14/146) and 19.2% (5/26), respectively. In univariable analysis, baseline nodal involvement, higher estrogen receptor (ER) expression, and premenopausal status were associated with RCB-III; only the first two factors remained statistically significant after Holm correction. In multivariable analysis, all three factors were statistically significant. Conclusions. These findings support the potential use of NET as the sole preoperative systemic therapy in selected patients: 88.6% underwent surgery without NACT. Individualized treatment selection and regular response assessment are essential. The identified factors may help refine patient selection criteria. The prognostic significance of residual cancer burden requires further investigation incorporating long-term outcomes and accounting for adjuvant therapy.

Medical alphabet(27)
Pirogov Russian National Research Medical University (RU), Russian Cancer Research Center NN Blokhin (RU), Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky (RU), Ministry of Health of the Russian Federation (RU), Botkin Hospital (RU)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon